menu
    • menu

    Company profile for Renovion

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Renovion is a clinical stage pharmaceutical company with a nebulized therapy that restores mucus clearance and reduces inflammation in the lungs. We are focused on developing ARINA-1 for orphan chronic inflammatory lung diseases. ​ With over 25 patient years of experience, ARINA-1 is poised to start clinical studies in lung transplant, cystic fibrosis (CF) and non-CF bronchiectasis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RenovionUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    900 MLK Jr. Blvd, Suite A Chapel Hill, NC 27514
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.renovion.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Renovion Positive Ph2 CLIMB Results for ARINA-1 in Bronchiectasis
    Renovion Positive Ph2 CLIMB Results for ARINA-1 in Bronchiectasis

    30 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240430987354/en

    BUSINESSWIRE
    30 Apr 2024
    Share Share
    Renovion Completes Enrollment in Phase 2 CLIMB Study in Bronchiectasis
    Renovion Completes Enrollment in Phase 2 CLIMB Study in Bronchiectasis

    11 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240111664650/en

    BUSINESSWIRE
    11 Jan 2024
    Share Share
    First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1
    First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1

    18 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230418005819/en

    BUSINESSWIRE
    18 Apr 2023
    Share Share
    Renovion enrols first subject in Phase II bronchiectasis therapy trial
    Renovion enrols first subject in Phase II bronchiectasis therapy trial

    03 Nov 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/renovion-bronchiectasis-therapy-trial/

    CLINICALTRIALSARENA
    03 Nov 2022
    Share Share
    Renovion Announces First Patient Enrolled in Ph2 Study Evaluating ARINA-1
    Renovion Announces First Patient Enrolled in Ph2 Study Evaluating ARINA-1

    02 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221102005149/en

    BUSINESSWIRE
    02 Nov 2022
    Share Share
    Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program
    Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program

    02 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220802005291/en

    BUSINESSWIRE
    02 Aug 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search